Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OraSure Technologies Inc.
Genmab's Arzerra disappoints in Phase II trial in common lymphoma
Genmab's anti-CD20 monoclonal antibody drug Arzerra (ofatumumab) has resulted in a low response rate in a single-arm, single-agent Phase II trial testing it as a therapy for relapsed diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma (NHL). However, the company and analysts attributed the "disappointing" result to its use without chemotherapy and a heavily pre-treated population, and a Phase III trial in DLBCL is continuing.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
OraSure Technologies Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice